Kintara Therapeutics (KTRA)
NASDAQ:KTRA
Holding KTRA?
Track your performance easily

Kintara Therapeutics (KTRA) Income Statement

799 Followers

Kintara Therapeutics Income Statement

Last quarter (Q4 2024), Kintara Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q4, Kintara Therapeutics's net income was $-2.33M. See Kintara Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 24Jun 23Jun 22Jun 21Jun 20
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 8.45M$ 8.45M$ 14.80M$ 22.67M$ 38.29M$ 8.14M
Operating Income
$ -8.31M$ -8.31M$ -14.66M$ -22.67M$ -38.29M$ -8.14M
Net Non Operating Interest Income Expense
--$ -137.00K-$ 30.00K$ 75.00K
Other Income Expense
--$ 10.00K$ -16.72M$ -16.72M$ -1.06M
Pretax Income
$ -8.32M$ -8.32M$ -14.65M$ -22.66M$ -38.30M$ -9.13M
Tax Provision
$ -17.00K$ -17.00K-$ -196.00K--
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -8.50M$ -8.50M$ -15.02M$ -25.13M$ -41.50M$ -9.14M
Basic EPS
$ -0.32$ -0.32$ -9.27$ -0.52$ -80.00$ -0.87
Diluted EPS
$ -0.32$ -0.32$ -9.27$ -0.52$ -80.00$ -0.87
Basic Average Shares
$ 105.41M$ 26.35M$ 1.62M$ 48.70M$ 517.72K$ 10.44M
Diluted Average Shares
$ 105.41M$ 26.35M$ 1.62M$ 48.70M$ 517.72K$ 10.44M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 8.45M$ 8.45M$ 14.80M$ 22.67M$ 38.29M$ 8.14M
Net Income From Continuing And Discontinued Operation
$ -8.32M$ -8.32M$ -14.65M$ -22.66M$ -38.30M$ -9.13M
Normalized Income
$ -8.28M$ -8.34M$ -11.57M--$ -8.07M
Interest Expense
------
EBIT
$ -8.34M$ -8.34M$ -14.80M$ -22.66M$ -38.33M$ -8.14M
EBITDA
$ -8.28M$ -8.28M$ -14.74M$ -22.60M$ -38.20M$ -8.13M
Currency in USD

Kintara Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis